ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 144 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9 | -25.0% | 667 | 0.0% | 0.00% | – |
Q1 2024 | $12 | -33.3% | 667 | -64.4% | 0.00% | – |
Q4 2023 | $18 | -21.7% | 1,875 | -9.6% | 0.00% | – |
Q3 2023 | $23 | -85.9% | 2,073 | -72.9% | 0.00% | -100.0% |
Q2 2023 | $163 | -51.3% | 7,638 | -7.8% | 0.00% | -66.7% |
Q1 2023 | $335 | -18.9% | 8,284 | -6.7% | 0.00% | -25.0% |
Q4 2022 | $413 | -99.9% | 8,881 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $461,000 | +15.0% | 8,881 | +4.7% | 0.00% | 0.0% |
Q2 2022 | $401,000 | -32.9% | 8,482 | +1.0% | 0.00% | -20.0% |
Q1 2022 | $598,000 | -54.3% | 8,396 | -52.0% | 0.01% | 0.0% |
Q4 2021 | $1,308,000 | +155.5% | 17,496 | +94.3% | 0.01% | +25.0% |
Q3 2021 | $512,000 | +27.0% | 9,004 | -1.6% | 0.00% | +33.3% |
Q2 2021 | $403,000 | +94.7% | 9,153 | +173.4% | 0.00% | -25.0% |
Q4 2019 | $207,000 | -23.9% | 3,348 | +3.7% | 0.00% | -33.3% |
Q2 2019 | $272,000 | +4.2% | 3,228 | +18.0% | 0.01% | 0.0% |
Q1 2019 | $261,000 | -17.1% | 2,736 | +0.8% | 0.01% | -25.0% |
Q2 2018 | $315,000 | – | 2,714 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 1,599,109 | $63,277,000 | 8.68% |
SENZAR ASSET MANAGEMENT, LLC | 566,903 | $22,432,000 | 6.58% |
Sarissa Capital Management LP | 105,000 | $4,155,000 | 1.60% |
INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 136,637 | $5,407,000 | 1.41% |
RA Capital Management | 250,000 | $9,893,000 | 1.17% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 110,515 | $4,373,000 | 0.99% |
Ghost Tree Capital, LLC | 35,000 | $1,385,000 | 0.75% |
WALL STREET ASSOCIATES | 159,100 | $6,296,000 | 0.65% |
BAILARD, INC. | 91,500 | $3,621,000 | 0.56% |
EAM Investors, LLC | 62,768 | $2,484,000 | 0.50% |